



CALIFORNIA TECHNOLOGY  
ASSESSMENT FORUM<sup>SM</sup>

---

# **Newest Treatments for Hepatitis C, Genotype 1**

**Questions for Deliberation**

**December 18, 2014**

# Comparative *Clinical Effectiveness* Example Question

Is the evidence “**adequate**” to demonstrate that “**intervention A**” is superior to “**comparator B**” for patients with “**condition X**”?

1. **Yes**
2. **No**


# Care Value



# Care Value Example Question

From the perspective of a Medicaid program, what is the care value of “**intervention A**” vs “**comparator B**”?

- A. **Low**
- B. **Reasonable**
- C. **High**



# Health System Value



# Health System Value Example Question

Assuming baseline pricing and payment mechanisms, what would be the **health system value** of “**intervention A**” for a state Medicaid program?

- A. **Low**
- B. **Reasonable**
- C. **High**



# Practice Question

**Will this year's rainfall make up for the years of drought?**

- A. Absolutely yes!**
- B. Yes, but it will take a while**
- C. There's a drought?**

# LDV/SOF vs. PR

See evidence at a glance pages 2-5

**Q1.** For patients with genotype 1 chronic hepatitis C infection, is the evidence adequate to demonstrate that clinical outcomes with *ledipasvir/sofosbuvir* are superior to those provided by treatment with *pegylated interferon plus ribavirin*?

1. Yes
2. No



# LDV/SOF vs. SOF + PR

See evidence at a glance pages 2-5

**Q2.** For patients with genotype 1 chronic hepatitis C infection, is the evidence adequate to demonstrate that clinical outcomes with *ledipasvir/sofosbuvir* are superior to those provided by treatment with *sofosbuvir plus pegylated interferon plus ribavirin*?

1. Yes
2. No

# LDV/SOF vs. SMV+SOF

See evidence at a glance pages 2-5

**Q3.** For patients with genotype 1 chronic hepatitis C infection, is the evidence adequate to demonstrate that clinical outcomes with *ledipasvir/sofosbuvir* are superior to those provided by treatment with *simeprevir plus sofosbuvir*?

1. Yes
2. No

# LDV/SOF vs. 3D + R

See evidence at a glance pages 2-5

**Q4.** For patients with genotype 1 chronic hepatitis C infection, is the evidence adequate to demonstrate that clinical outcomes with *ledipasvir/sofosbuvir* are superior to those provided by treatment with *3D + R* (*combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir with ribavirin*)?

1. Yes
2. No

# LDV/SOF vs. PR: Care Value

See evidence at a glance pages 5-10

**Q5.** If yes to question 1, given the prices presented in the report, what is the care value of *ledipasvir/sofosbuvir vs. pegylated interferon plus ribavirin*?

- A. Low
- B. Reasonable
- C. High



# LDV/SOF vs. PR: Health System Value

See evidence at a glance pages 5-10

**Q6.** Assuming no changes to pricing or to payment mechanisms, if a policy strategy to treat all known infected patients was adopted, what would be the health system value of *ledipasvir/sofosbuvir* for a state Medicaid program?

- A. Low
- B. Reasonable
- c. High

